Gilead Raday, COO, Redhill Biopharma, a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases talks about the growing problem of antibiotic resistance and the challenges this presents treating H. pylori infections, which affects about half of the global population. Redhill is working to bring Talicia, a new treatment for H. pylori to market potentially this year giving patients a new effective option for H. pylori infection.
#RDHL $RDHL #Hpylori #IBD #GI
@RedHillBio
Redhillbio.com
Download the transcript here.
Empowered Patient Podcast